Peregrine Pharmaceuticals to Present at Rodman and Renshaw Techvest 2nd Annual Security & Connectivity Investor Conference

Clinical Data Published in Neurosurgery Shows Peregrine Pharmaceuticals' Cotara(R) Holds Promise for Treating Brain Cancer

Peregrine Pharmaceuticals Receives FDA Clearance to Initiate Tarvacin(TM) Anti-Viral Clinical Trial

Data Published in Cancer Research Shows That Tarvacin(TM) Equivalent Plus Docetaxel Inhibits Breast Tumor Growth by 93%

Peregrine Pharmaceuticals Submits Tarvacin(TM) Anti-Viral Investigational New Drug Application

Peregrine Pharmaceuticals' Presentation Time at Investors Conference Changed to 10:50 a.m. EDT on April 28

Peregrine Pharmaceuticals to Present at Wall Street Reporter Investors Conference

Peregrine Pharmaceutical's Tarvacin(TM) Effective in Imaging Prostate Cancer

Vascular Targeting Agent Effectively Inhibits Prostate Cancer Growth and Metastasis

Tarvacin(TM) Equivalent (3G4) Plus Radiation Reduces Lung Tumor Growth By Over 95%